People In Brief
This article was originally published in The Gray Sheet
Executive SummaryAbiomed resignation: Chief Financial Officer Daniel J. Sutherby left the cardiac assist device firm Oct. 1, according to an Oct. 2 Securities and Exchange Commission filing, which identifies Ian McLeod, Abiomed's corporate controller, as acting CFO. On the following day, the company reaffirmed its fiscal year 2009 revenue guidance of $75-$80 million, up from $58.9 million in fiscal 2008. While the resignation is "not ideal," said Morgan Stanley device analyst David R. Lewis, it is probably more reflective of changing strategic needs in the company following the June launch of the Impella 2.5 assist device (1"The Gray Sheet" June 9, 2008, p. 20), rather than "any ominous development.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.